^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ulenistamab (PBP1510)

    i
    Other names: PBP1510
    Company:
    Prestige BioPharma
    Drug class:
    ZG16B inhibitor
    2ms
    ZG16B: A key regulator of tumor progression and immune microenvironment modulation in cancer (Review). (PubMed, Int J Mol Med)
    Furthermore, a clinical trial is currently testing the efficacy and safety of PBP1510, a humanized ZG16B antibody, for the treatment of advanced pancreatic cancer. In conclusion, ZG16B may be considered a novel target for cancer diagnosis, prognosis and therapy.
    Review • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ZG16B (Zymogen Granule Protein 16B)
    |
    ulenistamab (PBP1510)
    almost2years
    PAUF-I: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Prestige Biopharma Limited
    Trial completion date • Trial primary completion date • Metastases
    |
    ZG16B (Zymogen Granule Protein 16B)
    |
    gemcitabine • ulenistamab (PBP1510)
    almost3years
    PAUF-I: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Prestige Biopharma Limited | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date
    |
    gemcitabine • ulenistamab (PBP1510)
    over3years
    A clinical study assessing ZG16B/PAUF overexpression in high-grade ovarian serous adenocarcinoma (ESGE 2022)
    Recently, a new anti-PAUF/ZG16B antibody, PBP1510, was developed by PrestigeBiopharma (NCT05141149). This study provides arguments in support of a future clinical trial to evaluate this antibody in patients with ovarian cancer.
    Clinical
    |
    ZG16B (Zymogen Granule Protein 16B)
    |
    ulenistamab (PBP1510)
    almost4years
    First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. (ASCO 2022)
    The efficacy and safety data presented here, along with the data from in vivo mouse studies demonstrating superior anti-tumour activity of PBP1510 treatment, support further clinical development of PBP1510 as a novel anti-cancer agent to treat PAUF-positive PC. The pivotal step of advancing PBP1510 into initial human studies is now in progress.
    Preclinical
    |
    ZG16B (Zymogen Granule Protein 16B)
    |
    ZG16B positive
    |
    ulenistamab (PBP1510)